Skip to content
Bomb Report – Lifestyle
Author:
Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
September 24, 2026
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
September 2, 2026
Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
August 4, 2026
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 14, 2026
Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
May 6, 2026
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
April 7, 2026
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2026
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
March 31, 2026